| Pemphigus and pemphigoid diseases: in memoriam Detlef Zillikens E Schmidt, RJ Ludwig, F Caux, AS Payne, CD Sadik, T Hashimoto, ... Frontiers in Immunology 15, 1426834, 2024 | | 2024 |
| From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus R Rodriguez, TE Sivesind, D Murrell, RP Dellavalle JMIR dermatology 6 (1), e46812, 2023 | | 2023 |
| A life for autoimmune blistering diseases: in memoriam Detlef Zillikens JE Hundt, CD Sadik, N van Beek, H Busch, F Caux, M Goebeler, ... Frontiers in Immunology 14, 1291590, 2023 | | 2023 |
| Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases H Tseng, C Stone, DF Murrell Frontiers in Immunology 14, 1243581, 2023 | | 2023 |
| Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II A Patsatsi, M Daneshpazhooh, S Tavakolpour, H Mahmoudi, DF Murrell Frontiers in Medicine 10, 1268285, 2023 | | 2023 |
| The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial NJ Patel, DRW Jayne, PA Merkel, P Bekker, Y Zhang, PJ McDowell, ... The Lancet Rheumatology 5 (7), e413-e421, 2023 | 4 | 2023 |
| BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study D Murrell, A L. Bruckner, E Sprecher, D Kiritsi, L Maher, T Cunningham, ... British Journal of Dermatology 188 (Supplement_4), ljad113. 144, 2023 | 2 | 2023 |
| An abridged version of the Glucocorticoid Toxicity Index (GTI), the GTI-Metabolic Domains (GTI-MD): a post hoc analysis from the ADVOCATE trial NJ Patel, DRW Jayne, PA Merkel, P Bekker, Y Zhang, PJ McDowell, ... The Lancet Rheumatology, LANRHE814, 2023 | | 2023 |
| 639 Design of marigold-bp: A phase 2/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid P Joly, HV Patel, RR Cella, L Kephart, D Murrell Journal of Investigative Dermatology 143 (5), S109, 2023 | | 2023 |
| 396 A novel investigator global assessment score for the evaluation of keratosis pilaris MA Wang, A Wilson, B Daniel, ADL Rivero, L Martin, JS Kern, D Murrell Journal of Investigative Dermatology 143 (5), S68, 2023 | | 2023 |
| 459 Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis Y Tada, S Takeoka, L Spelman, D Murrell, C Chu, W Chung, J Wu, P Zoob, ... Journal of Investigative Dermatology 143 (5), S79, 2023 | | 2023 |
| 390 Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases J Johal, T Cowan, A Bilgic, B Bozca, S Enli, B Yang, M Daneshpazhooh, ... Journal of Investigative Dermatology 143 (5), S67, 2023 | | 2023 |
| Tildrakizumab for the treatment of exfoliative cheilitis T COWAN, NABU ALRUB, A WİLSON, M MAKHİJA, D MURRELL Mucosa 6 (1), 19-21, 2023 | | 2023 |
| Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study JS Kern, E Sprecher, MF Fernandez, F Schauer, C Bodemer, ... British Journal of Dermatology 188 (1), 12-21, 2023 | 23 | 2023 |
| 070 Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod R Hall, DA Culton, Z Liu, H Ujiie, E Schmidt, D Murrell, I Stoykov, ... Journal of Investigative Dermatology 142 (12), S192, 2022 | | 2022 |
| Intralesional 9‐valent human papillomavirus as a treatment for facial squamous cell carcinoma. A Wilson, TL Cowan, D Marucci, DF Murrell Journal of the European Academy of Dermatology & Venereology 36 (12), 2022 | 2 | 2022 |
| Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) L Borradori, N Van Beek, C Feliciani, B Tedbirt, E Antiga, R Bergman, ... Journal of the European Academy of Dermatology and Venereology 36 (10), 1689 …, 2022 | 78 | 2022 |
| Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris DF Murrell, A Patsatsi, P Stavropoulos, S Baum, T Zeeli, JS Kern, ... J Eur Acad Dermatol Venereol., 2022 | 4 | 2022 |
| Long-term efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor (1, 4, 5) modulator, for moderate-to-severe atopic dermatitis: results from the … E Guttman-Yassky, R Bissonette, L Kircik, D Murrell, FI Kuo, K Liu, ... BRITISH JOURNAL OF DERMATOLOGY 187 (3), E128-E129, 2022 | 1 | 2022 |
| A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa AS Paller, E Pope, D Rudin, A Malyala, D Ramsdell, R Johnson, H Landy, ... Orphanet journal of rare diseases 17 (1), 314, 2022 | 4 | 2022 |
A/Professor Deshan SebaratnamFaculty of Medicine, University of New South Wales在 unsw.edu.au 的电子邮件经过验证
